Spots Global Cancer Trial Database for A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
Official Title: An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC)
Study ID: NCT01589419
Conditions
Study Description
Brief Summary: An open-label, Phase 1b, dose escalation study evaluating the safety and tolerability of the PARP inhibitor Veliparib in combination with capecitabine and radiation in subjects with locally advanced rectal cancer (LARC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site Reference ID/Investigator# 99095, Scottsdale, Arizona, United States
Site Reference ID/Investigator# 68044, Chicago, Illinois, United States
Site Reference ID/Investigator# 112395, Goshen, Indiana, United States
Site Reference ID/Investigator# 68045, Durham, North Carolina, United States
Site Reference ID/Investigator# 68043, Madison, Wisconsin, United States
Site Reference ID/Investigator# 67882, East Melbourne, , Australia
Contact Details
Name: Philip Komarnitsky, MD
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
